Atlas Trials

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)

Clinical trial NCT03591731 · COMPLETED

Trial details

NCT number
NCT03591731
Sponsor
Intergroupe Francophone de Cancerologie Thoracique
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Neuroendocrine Carcinoma
Start date
2019-01-02
Primary completion
2021-07-09
Enrollment
185

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.